Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (MDGL) is a clinical-stage biopharmaceutical company pioneering treatments for metabolic dysfunction-associated steatohepatitis (MASH), including its FDA-approved therapy Rezdiffra. This page provides investors and healthcare professionals with timely updates on corporate milestones, clinical research, and regulatory developments.
Access the latest press releases, earnings reports, and scientific announcements in one centralized location. Key updates include Rezdiffra's commercialization progress, new clinical data analyses, and strategic partnerships advancing MASH treatment innovation. Our curated news collection ensures you stay informed about material events without speculative commentary.
Regular updates cover regulatory submissions, trial expansions, financial disclosures, and patient access initiatives. Content is rigorously verified to provide accurate, actionable information for investment and therapeutic decision-making. Bookmark this page to monitor Madrigal's progress in addressing critical unmet needs in liver disease therapeutics.
Madrigal (NASDAQ: MDGL) will present new clinical and real-world data for Rezdiffra (resmetirom) at AASLD The Liver Meeting, Nov 7-11, 2025 in Washington, D.C.
Key items include two oral presentations (Nov 9 and Nov 10) reporting two-year biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial, posters on response durability and effects after treatment interruption, and multiple real-world analyses of Rezdiffra use.
Notable data cited: Rezdiffra achieved primary endpoints in the MAESTRO-NASH biopsy trial and 91% of patients on 100 mg showed VCTE improvement or stabilization at one year.
Madrigal Pharmaceuticals (NASDAQ: MDGL) will release its third-quarter 2025 financial results on Tuesday, November 4, 2025 prior to the open of U.S. markets. Management will host a live webcast at 8:00 a.m. Eastern Time the same day to review financial and operating results.
Investors can access the live webcast via the company’s Investor Relations website and are advised to register at least 15 minutes before the start time. A replay will be available approximately two hours after the live webcast.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced inducement equity awards granted on October 15, 2025 to 19 new non-executive employees under its 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The grants aggregate to 889 stock options with an exercise price of $433.45 (equal to the closing price on the grant date) and 8,581 time-based restricted stock units (RSUs). Option vesting: 25% of option shares vest on the first anniversary, then 6.25% each quarterly anniversary thereafter. RSUs vest in four equal annual installments on each of the first through fourth anniversaries. All vesting is subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced inducement equity awards granted on October 1, 2025 to 27 new non-executive employees under its 2025 Inducement Plan.
The awards, approved by the independent Compensation Committee consistent with Nasdaq Listing Rule 5635(c)(4), comprise options to purchase 1,602 shares and 10,973 time‑based restricted stock units (RSUs) in the aggregate. Option exercise price is $449.14 per share (closing price on grant date).
Vesting: options vest 25% at one year then 6.25% each quarter thereafter; RSUs vest in four equal annual installments. All vesting is conditioned on continued employment as of each vesting date.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in MASH therapeutics, has announced equity inducement awards for 76 new non-executive employees under its 2025 Inducement Plan. The awards, approved by the company's Compensation Committee under Nasdaq Rule 5635(c)(4), include:
The grants consist of options to purchase 2,015 shares of common stock at $425.60 per share and 31,821 time-based restricted stock units. Options vest 25% after one year, followed by 6.25% quarterly thereafter. Restricted stock units vest in four equal annual installments, subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has announced equity inducement awards for new employees. The company granted a total of 4,510 time-based restricted stock units to 17 new non-executive employees on September 1, 2025.
The awards, approved under Madrigal's 2025 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments. The vesting is contingent upon continued employment through each vesting date.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced its upcoming participation in the Morgan Stanley 23rd Annual Global Health Care Conference. The presentation is scheduled for Monday, September 8, 2025, at 7:45 A.M. EDT.
Investors can access the live webcast through the provided link or via Madrigal's Investor Relations Events and Presentations page. A replay will be made available following the event.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has granted equity inducement awards to 11 new non-executive employees.
Under the company's 2025 Inducement Plan, the employees received a total of 6,940 time-based restricted stock units. These units will vest in four equal annual installments, subject to continued employment. The awards were approved by Madrigal's independent Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Pharmaceuticals (NASDAQ:MDGL) has received European Commission approval for Rezdiffra (resmetirom), making it the first and only approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis in the European Union.
The conditional marketing authorization is based on successful Phase 3 MAESTRO-NASH trial results, where 91% of patients treated with Rezdiffra 100 mg showed improvement or stabilization of liver stiffness at one year. The once-daily oral treatment targets approximately 370,000 diagnosed patients across Europe.
Madrigal plans to launch Rezdiffra in Europe starting with Germany in Q4 2025, with other EU countries, Iceland, Liechtenstein, and Norway to follow based on individual reimbursement procedures.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's presentation is scheduled for Tuesday, August 12, 2025, at 10:30 A.M. EDT.
Investors can access the live webcast through the provided link or via Madrigal's Investor Relations Events and Presentations page. A replay will be made available following the event.
FAQ
What is the current stock price of Madrigal Pharmac (MDGL)?
What is the market cap of Madrigal Pharmac (MDGL)?
